FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Comp Oncol / The oncogenic pathways of papillomaviruses.
Veterinary and comparative oncology2020; 19(1); 7-16; doi: 10.1111/vco.12659

The oncogenic pathways of papillomaviruses.

Abstract: Papillomaviruses are oncogenic DNA viruses and induce hyperplastic benign lesions of both cutaneous and mucosal tissues in their various hosts, including many domestic and wild animals as well as humans. There are some Papillomavirus genotypes that can infect hosts different from their own, such as BPV 1 and BPV 2 originated from cattle, which can also infect horses and are responsible for fibroblastic tumours in horses. This review article summarizes the origin and evolution of papillomaviruses as an etiological agent in the historical process. The main focus in this review is the evaluation of the interactions between high-risk papillomavirus oncoproteins and programmed cell-death pathways. It further exemplifies the role of these interactions in the malignant cell transformation process. In parallel with this, the use and importance of the bovine model system to enlighten the papillomavirus-associated cancers is discussed with an in-depth examination. Furthermore, it focuses on the epidemiological situation of BPV infections in Turkey in the cattle herds.
© 2020 John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2020-11-02 PubMed ID: 33084187DOI: 10.1111/vco.12659Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article abstract delves into the oncogenic pathways of Papillomaviruses, and explores the interactions between high-risk papillomavirus oncoproteins and cell death pathways that facilitate malignant cell transformations. The use of bovine models to understand these processes and the epidemiological situation in Turkey are also discussed.

Understanding Papillomaviruses Origins and Evolution

  • The central premise of the article reviews the evolution and the historical role of papillomaviruses as agents that cause diseases. These are oncogenic DNA viruses known for inducing hyperplastic benign lesions in both cutaneous and mucosal tissues across various hosts, including domestic and wild animals, and humans as well.
  • Notably, some Papillomavirus genotypes, such as BPV 1 and BPV 2, can infect hosts different from their natural ones. Originated in cattle, these types can infect horses and are responsible for fibroblastic tumours in them.

Papillomavirus Oncoproteins and Their Interactions with Cell-Death Pathways

  • The research focuses on evaluating the interactions between high-risk papillomavirus oncoproteins and programmed cell-death pathways. These interactions typically play a central role in the transformation process of malignant cells.

The Bovine Model System in Understanding Papillomavirus-Associated Cancers

  • The article discusses the use and importance of the bovine model system to help provide deeper insights into the cancers associated with papillomavirus. Such models meticulously recreate the conditions of the disease and can help in understanding the nature, spread, and potential treatment alternatives for the condition.

Epidemiological Situation of BPV Infections in Turkey

  • Moreover, the study includes an analysis of the epidemiological situation of BPV infections in Turkey, focusing on cattle herds. It presents a discussion that concerns the patterns, causes, and effects of these infections within this specific region. This in-depth study could provide valuable information for the development of preventive measures to control the spread of BPV infections.

Cite This Article

APA
Kaynarcalidan O, Oğuzoğlu TÇ. (2020). The oncogenic pathways of papillomaviruses. Vet Comp Oncol, 19(1), 7-16. https://doi.org/10.1111/vco.12659

Publication

Veterinary and comparative oncology
ISSN: 1476-5829
NlmUniqueID: 101185242
Country: England
Language: English
Volume: 19
Issue: 1
Pages: 7-16

Researcher Affiliations

Kaynarcalidan, Onur
  • Institute for Virology Düsseldorf University Hospital, Heinrich-Heine-University, Düsseldorf, Germany.
Oğuzoğlu, Tuba Çiğdem
  • Department of Virology, Faculty of Veterinary Medicine, Ankara University, Ankara, Turkey.

MeSH Terms

  • Animals
  • Carcinogenesis
  • Cell Differentiation
  • Gene Expression Regulation, Viral
  • Genome, Viral
  • Humans
  • Papillomaviridae / genetics
  • Papillomaviridae / physiology
  • Papillomavirus Infections / veterinary
  • Papillomavirus Infections / virology

References

This article includes 127 references
  1. Ennaji MM. Emergence of oncogenic high-risk human papillomavirus types and cervical cancer. 2019:539-570.
  2. Karamanou M, Agapitos E, Kousoulis A, Androutsos G. From the humble wart to HPV: a fascinating story throughout centuries. Oncol Rev 2010;4:133-135.
  3. von Krogh G. Genitoanal papillomavirus infection: diagnostic and therapeutic objectives in the light of current epidemiological observations. Int J STD AIDS 1991;2:391-404.
  4. Syrjänen S, Syrjänen K. The history of papillomavirus research. Cent Eur J Public Health 2008;16(Suppl):S7-S13.
  5. Lowy R, Douglas MS. Papillomavirus research: from natural history to vaccines and beyond. 2006:13-18.
  6. Pennycook KB, McCready TA. Condyloma Acuminata. StatPearls 2019.
  7. Frias-De-Diego A, Jara M, Escobar LE. Papillomavirus in wildlife. Front Ecol Evol 2019;7:1-11.
    doi: 10.3389/fevo.2019.00406google scholar: lookup
  8. Rigoni-Stern null. Statistical facts about cancers on which doctor Rigoni-stern based his contribution to the Surgeons' subgroup of the IV congress of the Italian scientists on 23 September 1842. (translation). Stat Med 1987;6:881-884.
  9. Aviles NB. The little death: Rigoni-stern and the problem of sex and cancer in 20th-century biomedical research. Soc Stud Sci 2015;45:394-415.
  10. Spurgeon ME, Lambert PF. Mus musculus papillomavirus 1: a New frontier in animal models of papillomavirus pathogenesis. J Virol 2020;94(9):1-13.
  11. Kreider JW, Bartlett GL. The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression. Adv Cancer Res 1981;35:81-110.
  12. Shope RE, Hurst EW. Infectious papillomatosis of rabbits: with a note on the histopathology. J Exp Med 1933;58:607-624.
  13. Root JJ, Hopken MW, Gidlewski T, Piaggio AJ. Cottontail rabbit papillomavirus infection in a desert cottontail (Sylvilagus audubonii) from Colorado, USA. J Wildl Dis 2013;49:1060-1062.
  14. Olson C, Cook RH. Cutaneous sarcoma-like lesions of the horse caused by the agent of bovine papilloma. Proc Soc Exp Biol Med 1951;77:281-284.
  15. zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res 1976;36:794.
  16. Munnolli SS, Pujar SM, Kademani BS. Scientometric portrait of Nobel Laureate Harald zur Hausen. ALIS 2011;58(1):71-78.
  17. Oğuzoğlu TÇ, Timurkan MÖ, Koç BT, Alkan F. Comparison of genetic characteristics of canine papillomaviruses in Turkey. Infect Genet Evol 2017;55:372-376.
  18. Oğuzoğlu TÇ, Koç BT, Akkutay-Yoldar Z, Salar S, Baştan A. Detection and whole genomic characterization of bovine papillomavirus type 1 associated with severe mammary cutaneous warts in Turkey. Vet Méx OA 2019;6(3):1-11.
  19. Bauermann FV, Joshi LR, Mohr KA. A novel bovine papillomavirus type in the genus Dyokappapapillomavirus. Arch Virol 2017;162:3225-3228.
  20. Rector A, Van Ranst M. Animal papillomaviruses. Virology 2013;445:213-223.
  21. Van Doorslaer K. Evolution of the Papillomaviridae. Virology 2013;445:11-20.
  22. Akkutay-Yoldar Z, Oğuzoğlu T, Doğan F, Ataseven V. Detection of bovine papillomavirus in an equine cell line as a contaminant. Vlaams Diergeneeskd Tijdschr 2019;88(3):150-156.
  23. Egawa N, Egawa K, Griffin H, Doorbar J. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses 2015;7:3863-3890.
  24. Bernard HU. Coevolution of papillomaviruses with human populations. Trends Microbiol 1994;2:140-143.
  25. Gottschling M, Bravo IG, Schulz E. Modular organizations of novel cetacean papillomaviruses. Mol Phylogenet Evol 2011;59:34-42.
  26. Russo V, Roperto F, De Biase D. Bovine papillomavirus type 2 infection associated with papillomatosis of the amniotic membrane in water buffaloes (Bubalus bubalis). Pathogens 2020;9:262.
  27. Roperto S, Russo V, Corrado F, Munday JS, Falco DD, Roperto F. Detection of bovine Deltapapillomavirus DNA in peripheral blood of healthy sheep (Ovis aries). Transbound Emerg Dis 2018;65:758-764.
  28. Shadan FF, Villarreal LP. The evolution of small DNA viruses of eukaryotes: past and present considerations. Virus Genes 1995;11:239-257.
  29. Carvajal-Rodríguez A. Detecting recombination and diversifying selection in human alpha-papillomavirus. Infect Genet Evol 2008;8:689-692.
  30. Shah SD, Doorbar J, Goldstein RA. Analysis of host-parasite incongruence in papillomavirus evolution using importance sampling. Mol Biol Evol 2010;27:1301-1314.
  31. Willemsen A, Bravo IG. Origin and evolution of papillomavirus (onco)genes and genomes. Philos Trans R Soc Lond B Biol Sci 2019;374:20180303.
  32. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006;11:2286-2302.
  33. Van Doorslaer K, Chen Z, Bernard HU. ICTV virus taxonomy profile: Papillomaviridae. J Gen Virol 2018;99:989-990.
  34. Alp Avcı G. Genomic organization and proteins of human papillomavirus. Mikrobiyol Bul 2012;46:507-515.
  35. McBride AA. The papillomavirus E2 proteins. Virology 2013;445:57-79.
  36. Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol 2020;10:1-15.
  37. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550-560.
  38. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32(Suppl 1):S7-S15.
  39. Cossart YE, Thompson C, Rose B. Virology. 1995:1-34.
  40. Knipe DM, Howley PM. Papillomaviridae. 2013:1662-1703.
  41. Yeo-Teh NSL, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci 2018;19:1-27.
    doi: 10.3390/ijms19061706google scholar: lookup
  42. Silva MA, Altamura G, Corteggio A. Expression of connexin 26 and bovine papillomavirus E5 in cutaneous fibropapillomas of cattle. Vet J 2013;195:337-343.
  43. Doorbar J, Quint W, Banks L. The biology and life-cycle of human papillomaviruses. Vaccine 2012;30:F55-F70.
  44. Nkili-Meyong AA, Moussavou-Boundzanga P, Labouba I. Genome-wide profiling of human papillomavirus DNA integration in liquid-based cytology specimens from a Gabonese female population using HPV capture technology. Sci Rep 2019;9:1504.
  45. Brandt S, Tober R, Corteggio A. BPV-1 infection is not confined to the dermis but also involves the epidermis of equine sarcoids. Vet Microbiol 2011;150:35-40.
  46. Chinnam M, Goodrich DW. RB1, development, and cancer. Curr Top Dev Biol 2011;94:129-169.
  47. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-937.
  48. Liu X, Clements A, Zhao K, Marmorstein R. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 2006;281:578-586.
  49. Roperto S, De Tullio R, Raso C. Calpain3 is expressed in a proteolitically active form in papillomavirus-associated urothelial tumors of the urinary bladder in cattle (W Markotter, Ed.). PLoS One 2010;5:e10299.
  50. Ressler S, Scheiden R, Dreier K. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 2007;13:7067-7072.
  51. Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J Virol 1990;64:723-730.
  52. Münger K, Baldwin A, Edwards KM. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004;78:11451-11460.
  53. Duensing S, Münger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002;62:7075-7082.
  54. Woodworth CD, Bowden PE, Doniger J. Characterization of normal human exocervical epithelial cells immortalized in vitro by papillomavirus types 16 and 18 DNA. Cancer Res 1988;48:4620-4628.
  55. Roman A, Munger K. The papillomavirus E7 proteins. Virology 2013;445:138-168.
  56. Modrow S, Falke D, Truyen U, Schätzl H. Molekulare Virologie. Papillomaviren. 2010:p 499-518.
  57. Sánchez IE, Dellarole M, Gaston K, de Prat Gay G. Comprehensive comparison of the interaction of the E2 master regulator with its cognate target DNA sites in 73 human papillomavirus types by sequence statistics. Nucleic Acids Res 2008;36:756-769.
  58. Maufort JP, Shai A, Pitot H, Lambert PF. A role for HPV 16 E5 in cervical carcinogenesis. Cancer Res 2010;70:2924-2931.
  59. Maufort JP, Williams SMG, Pitot HC, Lambert PF. Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res 2007;67:6106-6112.
  60. Venuti A, Paolini F, Nasir L. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011;10:140.
  61. Conrad M, Bubb VJ, Schlegel R. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol 1993;67:6170-6178.
  62. Disbrow GL, Sunitha I, Baker CC, Hanover J, Schlegel R. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 2003;311:105-114.
  63. Petti L, Nilson LA, DiMaio D. Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J 1991;10:845-855.
  64. DiMaio D, Petti L. The E5 proteins. Virology 2013;445:99-114.
  65. Paaso A, Jaakola A, Syrjänen S, Louvanto K. From HPV infection to lesion progression: the role of HLA alleles and host immunity. ACY 2019;63:148-158.
  66. Wang JW, Roden RBS. L2, the minor capsid protein of papillomavirus. Virology 2013;445:175-186.
  67. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27.
  68. Suryadinata R, Sadowski M, Sarcevic B. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci Rep 2010;30:243-255.
  69. Duronio RJ, Xiong Y. Signaling pathways that control cell proliferation. Cold Spring Harb Perspect Biol 2013;5:1-12.
    doi: 10.1101/cshperspect.a008904google scholar: lookup
  70. Tripathi R, Rath G, Jawanjal P, Bharadwaj M, Mehrotra R. Cyclin D1 protein affecting global women's health by regulating HPV mediated adenocarcinoma of the uterine cervix. Sci Rep 2019;9:5019.
  71. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010;221:3-12.
  72. Griffin LM, Cicchini L, Pyeon D. Human papillomavirus infection is inhibited by host autophagy in primary human keratinocytes. Virology 2013;437:12-19.
  73. Tingting C, Shizhou Y, Songfa Z. Human papillomavirus 16E6/E7 activates autophagy via Atg9B and LAMP1 in cervical cancer cells. Cancer Med 2019;8:4404-4416.
  74. Roperto S, Russo V, De Falco F. Bovine papillomavirus E5 oncoprotein expression and its association with an interactor network in aggresome-autophagy pathway. Vet Microbiol 2019;233:39-46.
  75. Pickles S, Vigié P, Youle RJ. The art of mitochondrial maintenance. Curr Biol 2018;28:R170-R185.
  76. De Falco F, Urraro C, Cutarelli A, Roperto S. Bovine papillomavirus E5 oncoprotein upregulates parkin-dependent mitophagy in urothelial cells of cattle with spontaneous papillomavirus infection: a mechanistic study. Comp Immunol Microbiol Infect Dis 2020;70:101463.
  77. Massagué J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer and heritable disorders. Cell 2000;103:295-309.
  78. Liu Q, Ma L, Jones T. Subjugation of TGFβ signaling by human papilloma virus in head and neck squamous cell carcinoma shifts DNA repair from homologous recombination to alternative end-joining. Clin Cancer Res 2018;24(23):1-15.
  79. Bayin NS, Ma L, Thomas C. Patient-specific screening using high-grade glioma explants to determine potential radiosensitization by a TGF-β small molecule inhibitor. Neoplasia 2016;18:795-805.
  80. Kawarada Y, Inoue Y, Kawasaki F. TGF-β induces p53/Smads complex formation in the PAI-1 promoter to activate transcription. Sci Rep 2016;6:35483.
  81. Moody CA, Fradet-Turcotte A, Archambault J, Laimins LA. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc Natl Acad Sci USA 2007;104:19541-19546.
  82. Scott ME, Shvetsov YB, Thompson PJ. Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer 2013;133:1187-1196.
  83. Hong HS, Akhavan J, Lee SH. Proinflammatory cytokine TNFα promotes HPV-associated oral carcinogenesis by increasing cancer stemness. Int J Oral Sci 2020;12:1-10.
  84. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 2002;277:21730-21739.
  85. Peter ME, Hadji A, Murmann AE. The role of CD95 and CD95 ligand in cancer. Cell Death Differ 2015;22:549-559.
  86. Klapsinou E, Argyri E, Panotopoulou E. Bax and Bak expression in cervical smears of women with low-and high-risk HPV types: a study of 120 cases. J Cytol 2015;32:223-229.
  87. Garnett T, Duerksen-Hughes P. Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch Virol 2006;151:2321-2335.
  88. García-Sastre A. Ten strategies of interferon evasion by viruses. Cell Host Microbe 2017;22:176-184.
  89. Hong S, Laimins LA. Manipulation of the innate immune response by human papillomaviruses. Virus Res 2017;231:34-40.
  90. Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet 2019;20:657-674.
  91. Shaikh MH, Bortnik V, McMillan NAJ, Idris A. cGAS-STING responses are dampened in high-risk HPV type 16 positive head and neck squamous cell carcinoma cells. Microb Pathog 2019;132:162-165.
  92. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLOS Pathog 2008;4:e1000017.
  93. Beglin M, Melar-New M, Laimins L. Human papillomaviruses and the interferon response. J Interferon Cytokine Res 2009;29:629-635.
  94. Schwartz SL, Conn GL. RNA regulation of the antiviral protein 2′-5′-oligoadenylate synthetase. WIREs RNA 2019;10:e1534.
  95. Chang YE, Laimins LA. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 2000;74:4174-4182.
  96. Hong S, Mehta KP, Laimins LA. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J Virol 2011;85:9486-9494.
  97. Wan CK, Andraski AB, Spolski R. Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells. PNAS 2015;112:9394-9399.
  98. Ghosh M, Saha S, Bettke J. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. bioRxiv 2020:1-42.
    doi: 10.1101/2020.03.12.989384google scholar: lookup
  99. Amelio I, Melino G. Context is everything: extrinsic signalling and gain-of-function p53 mutants. Cell Death Discov 2020;6:16.
  100. Hebner C, Beglin M, Laimins LA. Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation. J Virol 2007;81:12740-12747.
  101. Hebner CM, Wilson R, Rader J, Bidder M, Laimins LA. Human papillomaviruses target the double-stranded RNA protein kinase pathway. J Gen Virol 2006;87:3183-3193.
  102. Kazemi S, Papadopoulou S, Li S. Control of alpha subunit of eukaryotic translation initiation factor 2 (eIF2 alpha) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2 alpha-dependent gene expression and cell death. Mol Cell Biol 2004;24:3415-3429.
  103. Munday JS. Bovine and human papillomaviruses: a comparative review. Vet Pathol 2014;51:1063-1075.
  104. He Z, Meng Q, Qiao J. Mixed nipple infections caused by variant of BPV3 and a putative new subtype of BPV in cattle. Transbound Emerg Dis 2016;63:e140-e143.
  105. Dagalp SB, Dogan F, Farzanı TA, Salar S, Bastan A. The genetic diversity of bovine papillomaviruses (BPV) from different papillomatosis cases in dairy cows in Turkey. Arch Virol 2017;162:1507-1518.
  106. Morgan IM, Grindlay GJ, Campo MS. Epithelial specific transcriptional regulation of the bovine papillomavirus 4 promoter by E2. J Gen Virol 1998;79(Pt 3):501-508.
  107. Borzacchiello G, Roperto F. Bovine papillomaviruses, papillomas and cancer in cattle. Vet Res 2008;39:45.
  108. Roperto S, Munday JS, Corrado F, Goria M, Roperto F. Detection of bovine papillomavirus type 14 DNA sequences in urinary bladder tumors in cattle. Vet Microbiol 2016;190:1-4.
  109. Somvanshi R. Papillomatosis in buffaloes: a less-known disease. Transbound Emerg Dis 2011;58:327-332.
  110. Ozkul IA, Aydin Y. Tumours of the urinary bladder in cattle and water buffalo in the Black Sea region of Turkey. Br Vet J 1996;152:473-475.
  111. Nasir L, Campo MS. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. Vet Dermatol 2008;19:243-254.
  112. Yuan Z, Gault EA, Campo MS, Nasir L. Different contribution of bovine papillomavirus type 1 oncoproteins to the transformation of equine fibroblasts. J Gen Virol 2011;92:773-783.
  113. Knottenbelt DC. A suggested clinical classification for the equine sarcoid. Clin Tech Equine Pract 2005;4:278-295.
  114. Marti E, Lazary S, Antczak DF, Gerber H. Report of the first international workshop on equine sarcoid. Equine Vet J 1993;25:397-407.
  115. Gobeil PAM, Yuan Z, Gault EA, Morgan IM, Campo MS, Nasir L. Small interfering RNA targeting bovine papillomavirus type 1 E2 induces apoptosis in equine sarcoid transformed fibroblasts. Virus Res 2009;145:162-165.
  116. Munday JS, Thomson N, Dunowska M, Knight CG, Laurie RE, Hills S. Genomic characterisation of the feline sarcoid-associated papillomavirus and proposed classification as Bos taurus papillomavirus type 14. Vet Microbiol 2015;177:289-295.
  117. Knowles G, O'Neil BW, Campo MS. Phenotypical characterization of lymphocytes infiltrating regressing Papillomas. J Virol 1996;70:8.
  118. Da Silva DM, Movius CA, Raff AB. Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a μ genotype. Virology 2014;0:279-286.
  119. Pang F, Chen Z, Wang C. Comprehensive analysis of differentially expressed microRNAs and mRNAs in MDBK cells expressing bovine papillomavirus E5 oncogene. PeerJ 2019;7:e8098.
  120. Araibi EH, Marchetti B, Ashrafi GH, Campo MS. Downregulation of major histocompatibility complex class I in bovine papillomas. J Gen Virol 2004;85:2809-2814.
  121. Ashrafi GH, Tsirimonaki E, Marchetti B. Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 2002;21:248-259.
  122. Campo MS. Vaccination against papillomavirus in cattle. Clin Dermatol 1997;15:275-283.
  123. Gil da Costa RM, Medeiros R. Bovine papillomavirus: opening new trends for comparative pathology. Arch Virol 2014;159:191-198.
  124. Pils S, Joura EA. From the monovalent to the nine-valent HPV vaccine. Clin Microbiol Infect 2015;21:827-833.
  125. Hainisch EK, Abel-Reichwald H, Shafti-Keramat S. Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in horse. J Gen Virol 2017;98:230-241.
  126. Campo MS. Animal models of papillomavirus pathogenesis. Virus Res 2002;89:249-261.
  127. Joh J, Chilton PM, Wilcher SA. T cell-mediated antitumor immune response eliminates skin tumors induced by mouse papillomavirus, MmuPV1. Exp Mol Pathol 2017;103:181-190.

Citations

This article has been cited 8 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.